Alzheimer’s Disease Diagnostics Market By Test Type (Biomarker-based Tests, Neuroimaging, Genetic Tests, Cerebrospinal Fluid (CSF) Tests, Blood Tests), By End-User (Hospitals, Diagnostic Laboratories, Research Institutes, Home Care Settings), By Technology (Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Electroencephalogram (EEG), Computed Tomography (CT), Genomic Sequencing), By Disease Stage (Early-stage Alzheimer’s, Mild Cognitive Impairment (MCI), Advanced Alzheimer’s), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Alzheimer’s Disease Diagnostics Market was valued at USD 9.3 billion in 2023 and will surpass USD 15.9 billion by 2030; growing at a CAGR of 8.0% during 2024 - 2030.

Test Type Segment is Largest Owing to Biomarker-Based Tests

The Alzheimer’s disease diagnostics market is driven by a variety of test types that aid in detecting and diagnosing the neurodegenerative disorder. Among these, biomarker-based tests have emerged as the largest subsegment due to their ability to identify specific proteins and abnormalities in the brain associated with Alzheimer’s. These tests help in early detection, allowing for timely intervention, which is crucial in managing the disease’s progression. The increasing availability of biomarkers such as amyloid plaques, tau proteins, and neurofilament light chains is enhancing the precision and reliability of these diagnostic methods.

Biomarker-based tests are widely recognized for their accuracy and non-invasive nature, which makes them preferred by healthcare professionals. As the global healthcare industry moves toward more personalized and precise diagnostics, these tests are becoming essential in early-stage Alzheimer’s detection. Their ability to identify Alzheimer’s risk at an earlier stage than traditional diagnostic methods is driving their growth. This trend is expected to continue as research advances in identifying new biomarkers that can further refine diagnostic capabilities, leading to an increased adoption of these tests in clinical settings.

End-User Segment is Fastest Growing Owing to Diagnostic Laboratories

In the Alzheimer’s disease diagnostics market, diagnostic laboratories represent the fastest-growing subsegment due to the increasing demand for accurate and reliable diagnostic services. These laboratories are equipped with advanced technologies and trained personnel capable of conducting a variety of tests to diagnose Alzheimer’s. The demand for diagnostic services is rising in tandem with the global increase in Alzheimer’s disease cases, creating a strong market for diagnostic laboratories. These laboratories play a key role in the accurate interpretation of biomarker-based tests, neuroimaging, and genetic testing, which are essential for early Alzheimer’s diagnosis.

Diagnostic laboratories also offer specialized services and possess the expertise to handle complex testing procedures, such as cerebrospinal fluid (CSF) analysis and genetic testing. As the global prevalence of Alzheimer’s disease continues to rise, diagnostic laboratories are expanding their capabilities to meet the growing demand. This trend is also supported by advances in diagnostic technologies, which allow laboratories to offer more precise and timely results, contributing to their rapid market growth.

Technology Segment is Largest Owing to Positron Emission Tomography (PET)

Within the technology segment of Alzheimer’s disease diagnostics, Positron Emission Tomography (PET) has established itself as the largest and most widely adopted method. PET imaging allows clinicians to visualize amyloid plaques and tau protein tangles in the brain, two hallmark features of Alzheimer’s disease. This non-invasive imaging technique provides crucial information that can help confirm a diagnosis or monitor disease progression. PET scans are particularly useful for detecting Alzheimer's at early stages, which is key to effective treatment and patient management.

The growing acceptance of PET as a reliable diagnostic tool for Alzheimer’s disease is driven by its ability to provide detailed brain imaging and detect changes even in the early stages of the disease. Moreover, advancements in PET imaging technologies, such as the development of new radiotracers, are making the technique even more accurate and accessible. These improvements, along with ongoing research in neuroimaging, ensure that PET will continue to be a dominant force in the Alzheimer’s diagnostics market.

Disease Stage Segment is Fastest Growing Owing to Early-Stage Alzheimer’s

The disease stage segment in the Alzheimer’s disease diagnostics market is rapidly evolving, with the fastest growth observed in the early-stage Alzheimer’s subsegment. Early detection is crucial for slowing down the progression of the disease, making early-stage Alzheimer’s a focal point in diagnostic research. This segment is experiencing significant growth as healthcare providers and researchers focus on identifying the disease at its onset to implement treatment options that can delay cognitive decline and improve the quality of life for patients.

Advances in biomarker identification, neuroimaging, and genetic testing are enabling the detection of Alzheimer’s disease in its earliest stages, sometimes even before significant cognitive symptoms appear. Early diagnosis is not only critical for patient outcomes but also for enabling patients to participate in clinical trials for new treatments. With ongoing advancements in diagnostic technologies and a growing emphasis on preventative healthcare, the early-stage Alzheimer’s subsegment is expected to remain the fastest-growing area within the disease stage category.

Regional Segment is Largest Owing to North America

In terms of geographical dominance, North America holds the largest share of the Alzheimer’s disease diagnostics market. The region benefits from a well-established healthcare infrastructure, high levels of healthcare expenditure, and an aging population, all of which contribute to the growing demand for Alzheimer’s diagnostics. The United States, in particular, is at the forefront of research and development in neurodegenerative diseases, with numerous companies and academic institutions focused on advancing diagnostic technologies.

North America also boasts strong regulatory support for the approval of innovative diagnostic tools, allowing for rapid commercialization of new technologies. The increasing prevalence of Alzheimer’s disease in the aging population, combined with rising awareness about the importance of early detection, is driving the expansion of the diagnostic market in this region. The ongoing focus on personalized medicine and precision diagnostics further fuels growth in North America, making it the largest regional market for Alzheimer’s disease diagnostics.

Competitive Landscape and Leading Companies

The competitive landscape of the Alzheimer’s disease diagnostics market is characterized by a mix of established global players and emerging companies focusing on innovative diagnostic solutions. Major companies such as Roche Holding AG, Biogen Inc., Siemens Healthineers, and GE Healthcare dominate the market, offering a broad range of diagnostic tests and technologies, from biomarker-based tests to neuroimaging and genetic testing. These companies are investing heavily in research and development to enhance diagnostic accuracy, reduce costs, and introduce new technologies to the market.

The competitive environment is also influenced by the growing interest in personalized medicine and the development of companion diagnostics for Alzheimer’s. Partnerships, mergers, and acquisitions are common as companies seek to strengthen their product offerings and expand their market share. For instance, strategic collaborations between diagnostic technology providers and pharmaceutical companies are becoming increasingly common to enable earlier and more accurate diagnosis, which is critical for the development of targeted therapies. As the Alzheimer’s diagnostics market continues to expand, the focus on innovation, regulatory approvals, and market penetration will define the competitive dynamics in the coming years.

List of Leading Companies:

• Roche Holding AG
• Eli Lilly and Co.
• Biogen Inc.
• Siemens Healthineers AG
• GE Healthcare
• Johnson & Johnson
• AbbVie Inc.
• Novartis AG
• Medtronic PLC
• Philips Healthcare
• AstraZeneca
• Quanterix Corporation
• Corteva Inc.
• Thermo Fisher Scientific
• Mindset Inc.

Recent Developments:

• Roche Holding AG launched a new PET scan technology in 2024, improving the early detection of Alzheimer’s-related brain changes.
• Biogen Inc. received FDA approval for a new Alzheimer’s diagnostic tool that combines biomarkers with neuroimaging to improve accuracy in diagnosis.
• Siemens Healthineers entered into a strategic partnership with a biotech firm in 2023 to co-develop innovative neuroimaging solutions for Alzheimer’s diagnosis.
• Eli Lilly and Co. completed the acquisition of a diagnostics startup in late 2023 to enhance its portfolio of Alzheimer’s biomarkers and diagnostic tests.
• Thermo Fisher Scientific launched a new genetic testing platform in 2024 aimed at early identification of genetic risk factors associated with Alzheimer’s disease.

Report Scope: